Search results | oncology

Reports

Personalized Medicine in Oncology Partnering Terms and Agreements

The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

Oncology Partnering Terms and Agreements

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies

Cancer Diagnostics Partnering Terms and Agreements

The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer diagnostics partnering contract documents Top cancer diagnostics deals by value   The more »

Cancer Monoclonal Antibody Partnering Terms and Agreements

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies

Cancer Vaccine Partnering Agreements

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Oncology partnering – recent deals analysis 2009-2014

Partnering in the last decade has seen an increase in oncology partnering with an increase in modern diagnostic technologies, according to recent partnering deals analysis

Onyx Pharmaceuticals: Oncology specialists and a subsidiary of Amgen

Onyx Pharmaceuticals is a biotechnology company based in San Francisco developing therapies for the treatment of people living with cancer.

Oncology partnering

A focus on oncology partnering for therapies, diagnostics and other interventions for the treatment and prevention of cancer

Personalized medicine in oncology: recent life science partnering trends

Scientists predict that the cure to cancer in the future lies in exploiting personalized medicine technology.

Dainippon Sumitomo Pharmaceuticals; Expanding in the markets of the US and oncology

Dainippon Sumitomo Pharmaceuticals is a Japanese based global research pharmaceutical company dedicated to creating pharmaceuticals for a range of human medical conditions.

Industry reports: Clovis Oncology looking to sell itself

Industry reports: Clovis Oncology Inc, a cancer-focused drugmaker, is considering selling itself, three people familiar with the deal told Reuters this week

Abbott Laboratories focus on CNS and oncology: Pharma partnering activity 2005-2013

Abbott Laboratories announced over 130 pharma partnering / licensing deals since 2005, with over 25 deals in 2012 alone

Sanofi inks pharma partnering ties with Massachusetts General Hospital for oncology research

Sanofi announced a two-year pharma partnering agreement with Massachusetts General Hospital (MGH) aimed at furthering translational medicine research to develop new treatments for various types of hematological malignancies and solid tumors

Servier seals a pharma partners pact with Ethical Oncology Science

Ethical Oncology Science and Servier, a big pharma company have sealed a pharma partners collaboration and license agreement to further develop EOS’ antitumor drug E-3810.

Big pharma Merck snags deal for oncology candidate vintafolide

Merck, a big pharma company has entered into a global development and marketing agreement to commercialize Endocyte’s novel therapeutic vintafolide (EC145)

Events

Sorry, your search returned no results.


Deals

Novartis and Aduro Biotech in immuno-oncology pact

Aduro Biotech announced the establishment of a major collaboration with Novartis

Kura Oncology licenses tipifarnib; banks $60 million financing

Kura Oncology has entered into an agreement with Janssen Pharmaceutica for an exclusive license to develop and commercialize tipifarnib in the field of oncology

Merck Serono and Illumina in oncology diagnostic pact

Illumina has formed a collaboration with Merck Serono to develop a universal next-generation sequencing (NGS)-based oncology diagnostic

Roche acquires Signature Diagnostics for access to translational oncology and genomics

Roche announced the acquisition of Signature Diagnostics

Curis and Aurigene in immuno-oncology pact

Curis and Aurigene Discovery Technologies have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets

Boehringer Ingelheim and Oxford BioTherapeutics in oncology pact

Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration

Medimmune licenses Omnis’ immuno-oncology program

MedImmune has entered into a licensing agreement with Omnis Pharmaceuticals

Pfizer and Kyowa Hakko Kirin start a pharma alliance for immuno-oncology study

Pfizer and Kyowa Hakko Kirin have entered into an pharma alliance agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab.

Collaboration agreement for oncology drug candidates targeting apoptosis regulation pathways

Servier have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways.

Novartis enters into m&a deal for immuno-oncology company

Novartis has agreed for an m&a deal with CoStim Pharmaceuticals for an undisclosed amount.